# Innocan Pharma Corp

Innocan Pharma Corp is an Asset Manager.

## Overview

- **Organization type:** Asset Manager
- **Assets under management:** Undisclosed
- **Website:** https://innocanpharma.com
- **LinkedIn:** https://www.linkedin.com/company/innocanpharma

## Regulatory record

- **Reports private funds:** No

## About

Innocan Pharma Corp was founded with a mission to develop novel drug-delivery technologies for cannabinoids and psychedelics, aiming to treat conditions such as pain, inflammation, and mental health disorders. The company is publicly listed on the Canadian Securities Exchange under the ticker INNO, and its structure is that of a pharmaceutical development firm rather than a family office. The company's strategy has included both research and development of proprietary formulations and the acquisition of intellectual property. It has partnered with institutions such as the Hebrew University of Jerusalem for drug-discovery programs. Its pipeline targets neurological and psychiatric indications, though no products have received regulatory approval as of the latest available data. By 2023, Innocan Pharma had not disclosed a team size or AUM, consistent with its biotech rather than asset-management profile. The company maintains a presence in Canada and Israel, reflecting its research partnerships. It has not disclosed additional offices or adjacent vehicles like a philanthropic foundation. As a publicly traded entity, Innocan Pharma is subject to securities regulation and quarterly reporting, starkly different from the privacy of a family office. Its structure as a single-purpose biotech company with no external capital-allocation function makes it an outlier for the Altss family-office database.

## Questions

### What is Innocan Pharma's core business?

Innocan Pharma develops proprietary drug-delivery technologies for cannabinoids and psychedelics, targeting pain, inflammation, and central nervous system disorders. It holds intellectual property and partners with academic institutions for preclinical research.

### Where is Innocan Pharma headquartered?

The company's registered address is in Canada, with operational activities and research partnerships in Israel. The exact headquarters city is not publicly specified in sources available.

### Has Innocan Pharma received regulatory approval for any drug?

As of public records, no Innocan Pharma product has received regulatory approval from Health Canada, the FDA, or any major health authority. The firm remains a preclinical-stage company.

### Who runs Innocan Pharma?

Public disclosure lists Iris Bincovich as CEO and a director, but the full team composition and background details are not extensively documented in available sources.

## Related profiles

- [Deep Fission](https://altss.com/profile/deep-fission-inc)
- [Invesco Galaxy Bitcoin ETF](https://altss.com/profile/invesco-galaxy-bitcoin-etf)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/innocan-pharma-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology